BioPharmSignal logoBioPharmSignal

Biotech News

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

Spero Therapeutics (SPRO)Spero TherapeuticsEarnings

Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in October 2025

Spero's development partner, GSK, plans to submit data from the PIVOT-PO trial as part of a planned US Food and Drug Administration (FDA) filing in 4Q 2025...

Related news

SPROSpero Therapeutics2026-05-13 21:05 EST

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-03-26 21:05 EST

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

ANTXAN2 Therapeutics2025-11-12 21:01 EST

AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

VIRIVirios Therapeutics2026-03-18 12:30 EST

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

VIRIVirios Therapeutics2025-11-06 13:45 EST

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

COCPCocrystal Pharma2025-11-14 13:00 EST

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

AVIRAtea2025-11-12 21:05 EST

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

BRNSBarinthus Biotherapeutics2025-11-07 12:30 EST

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

IMNNImunon2025-11-06 13:05 EST

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

View all latest news

Spero Therapeutics

Spero Therapeutics is an anti-infective company focused on bacterial infections and novel antibiotics. Its story is centered on addressing drug-resistant pathogens and difficult infection settings.

Recent company news

SPROSpero Therapeutics2026-08-05 21:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-08-04 21:01 EST

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Stock data

Close
1.27 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States